2023-07-27 04:54:00 ET
- Integra LifeSciences Holdings press release ( NASDAQ: IART ): Q2 Non-GAAP EPS of $0.71 beats by $0.14 .
- Revenue of $381.3M (-4.2% Y/Y) beats by $7.23M .
- Total reported revenues of $381.3 million declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year.
-
For the full year 2023, the Company is updating its revenue and adjusted EPS expectations to $1.548 to $1.560 billion ($1.56B consensus) and $3.10 to $3.18 ($3.12 consensus), respectively. The revenue range represents reported growth of -0.6% to 0.2%, with organic growth of 0.3% to 1.1% and reflects the full year impact of the Boston recall and the solid performance of the underlying business.
-
For the third quarter 2023, the Company expects reported revenues in the range of $386 million to $390 million ($388.59M consensus), representing reported growth of 0.2% to 1.3% and organic growth of 0.3% to 1.3%. Adjusted earnings per diluted share are expected to be in the range of $0.76 to $0.80 ($0.84 consensus), including the impact of the Boston recall.
For further details see:
Integra LifeSciences Holdings Non-GAAP EPS of $0.71 beats by $0.14, revenue of $381.3M beats by $7.23M